AstraZeneca and Ranbaxy Win a Closely Watched Pay-to-Delay Case – Pharmalot – WSJ
0
In a closely watched case, a federal court jury decided that a so-called pay-to-delay deal between AstraZeneca and Ranbaxy Laboratories involving the launch of a generic version of the Nexium heartburn pill was not anticompetitive.
This was the first time that a lawsuit over such deals went to trial since the U.S. Supreme Court ruled last year that drug makers can face greater antitrust scrutiny over pay-to-delay deals. In these arrangements, a brand-name drug maker reaches a settlement with a generic rival in exchange for ending patent litigation and an agreement allowing a copycat medicine to be launched at a future date.
Read more – Pharmalot – WSJ